eligibility_summary
Inclusion: ≥18, ECOG 0–1, life expectancy ≥12 wks, advanced solid tumors post standard therapy, washouts: chemo >3 wks, targeted >2 wks/5 half-lives, mAb >4 wks, palliative RT >2 wks, adequate organ function, measurable disease, CD24 tissue/biopsy. Exclude: prior CD24 therapy/transplant, active CNS mets, serious cardiac/pulmonary/GI/hepatic disease or long QTc, immunosuppression, HBV/HCV/HIV or severe infection, recent live vaccine/surgery/investigational Rx, pregnancy, other malignancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: IMM47, a humanized IgG monoclonal antibody (mAb) given IV q2w. Indication: adults with advanced solid tumors (Phase I, dose-escalation/expansion). Mechanism of action: binds tumor-expressed CD24, an innate immune “don’t‑eat‑me” signal, to block the CD24–Siglec‑10 checkpoint, thereby enhancing macrophage-mediated phagocytosis and antitumor immunity. The mAb may also engage Fc-dependent effector functions (ADCC/ADCP). Targets and pathways: CD24 on tumor cells, Siglec‑10 on macrophages, innate immune checkpoint and phagocytic pathways, Fcγ receptor signaling on macrophages/NK cells.